Gut microbiota links with cognitive impairment in amyotrophic lateral sclerosis: A multi-omics study

Zhenxiang Gong; Li Ba; Jiahui Tang; Yuan Yang; Zehui Li; Mao Liu; Chun Yang; Fengfei Ding; Min Zhang

doi:10.7555/JBR.36.20220198

Volume 37 Issue 2

Mar. 2023

Turn off MathJax

Article Contents

Abstract

References

Supplements

The Journal of Biomedical Research > 2023 > 37(2): 125-137. > DOI: 10.7555/JBR.36.20220198

Zhenxiang Gong, Li Ba, Jiahui Tang, Yuan Yang, Zehui Li, Mao Liu, Chun Yang, Fengfei Ding, Min Zhang. Gut microbiota links with cognitive impairment in amyotrophic lateral sclerosis: A multi-omics study[J]. The Journal of Biomedical Research, 2023, 37(2): 125-137. DOI: 10.7555/JBR.36.20220198

Citation:

PDF (2930 KB)

Gut microbiota links with cognitive impairment in amyotrophic lateral sclerosis: A multi-omics study

1.
Department of Neurology and Psychiatry, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China
2.
Department of Neurology, SUNY Downstate Medical Center, NY 11226, USA
3.
Department of Anesthesiology and Perioperative Medicine, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China
4.
Department of Pharmacology, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China

More Information

Corresponding author:
Fengfei Ding, Department of Pharmacology, School of Basic Medical Sciences; State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Institutes of Brain Science, Shanghai Medical College, Fudan University, 130 Dong'an Road, Xuhui District, Shanghai 200032, China. Tel: +86-21-54237900, E-mail: fengfei_ding@fudan.edu.cn

Min Zhang, Department of Neurology and Psychiatry, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Road, Qiaokou District, Wuhan, Hubei 430030, China. Tel: +86-27-83663895, E-mail: zhang_min_3464@126.com
Received Date: September 06, 2022
Revised Date: November 04, 2022
Accepted Date: November 21, 2022
Available Online: December 27, 2022

Graphical Abstract

Abstract

Abstract

Recently, cognitive impairments (CI) and behavioral abnormalities in patients with amyotrophic lateral sclerosis (ALS) have been reported. However, the underlying mechanisms have been poorly understood. In the current study, we explored the role of gut microbiota in CI of ALS patients. We collected fecal samples from 35 ALS patients and 35 healthy controls. The cognitive function of the ALS patients was evaluated using the Edinburgh Cognitive and Behavioral ALS Screen. We analyzed these samples by using 16S rRNA gene sequencing as well as both untargeted and targeted (bile acids) metabolite mapping between patients with CI and patients with normal cognition (CN). We found altered gut microbial communities and a lower ratio of Firmicutes/Bacteroidetes in the CI group, compared with the CN group. In addition, the untargeted metabolite mapping revealed that 26 and 17 metabolites significantly increased and decreased, respectively, in the CI group, compared with the CN group. These metabolites were mapped to the metabolic pathways associated with bile acids. We further found that cholic acid and chenodeoxycholic acid were significantly lower in the CI group than in the CN group. In conclusion, we found that the gut microbiota and its metabolome profile differed between ALS patients with and without CI and that the altered bile acid profile in fecal samples was significantly associated with CI in ALS patients. These results need to be replicated in larger studies in the future.
- amyotrophic lateral sclerosis,
- cognitive decline,
- gut microbiota,
- fecal metabolites,
- bile acids

FullText(HTML)

CLC number: R744.8, Document code: A

The authors reported no conflict of interests.

References (47)

References

[1]	Kiernan MC, Vucic S, Cheah BC, et al. Amyotrophic lateral sclerosis[J]. Lancet, 2011, 377(9769): 942–955. doi: 10.1016/S0140-6736(10)61156-7
[2]	Arnoriaga-Rodríguez M, Fernández-Real JM. Microbiota impacts on chronic inflammation and metabolic syndrome - related cognitive dysfunction[J]. Rev Endocr Metab Disord, 2019, 20(4): 473–480. doi: 10.1007/s11154-019-09537-5
[3]	Crockford C, Newton J, Lonergan K, et al. ALS-specific cognitive and behavior changes associated with advancing disease stage in ALS[J]. Neurology, 2018, 91(15): e1370–e1380. doi: 10.1212/WNL.0000000000006317
[4]	Chiò A, Ilardi A, Cammarosano S, et al. Neurobehavioral dysfunction in ALS has a negative effect on outcome and use of PEG and NIV[J]. Neurology, 2012, 78(14): 1085–1089. doi: 10.1212/WNL.0b013e31824e8f53
[5]	Elamin M, Phukan J, Bede P, et al. Executive dysfunction is a negative prognostic indicator in patients with ALS without dementia[J]. Neurology, 2011, 76(14): 1263–1269. doi: 10.1212/WNL.0b013e318214359f
[6]	Ye S, Ji Y, Li C, et al. The edinburgh cognitive and behavioural ALS screen in a Chinese amyotrophic lateral sclerosis population[J]. PLoS One, 2016, 11(5): e0155496. doi: 10.1371/journal.pone.0155496
[7]	Xu Z, Alruwaili ARS, Henderson RD, et al. Screening for cognitive and behavioural impairment in amyotrophic lateral sclerosis: frequency of abnormality and effect on survival[J]. J Neurol Sci, 2017, 376: 16–23. doi: 10.1016/j.jns.2017.02.061
[8]	Goldstein LH, Abrahams S. Changes in cognition and behaviour in amyotrophic lateral sclerosis: nature of impairment and implications for assessment[J]. Lancet Neurol, 2013, 12(4): 368–380. doi: 10.1016/S1474-4422(13)70026-7
[9]	Balendra R, Isaacs AM. C9orf72-mediated ALS and FTD: multiple pathways to disease[J]. Nat Rev Neurol, 2018, 14(9): 544–558. doi: 10.1038/s41582-018-0047-2
[10]	Zou Z, Zhou Z, Che C, et al. Genetic epidemiology of amyotrophic lateral sclerosis: a systematic review and meta-analysis[J]. J Neurol, Neurosurg, Psychiatry, 2017, 88(7): 540–549. doi: 10.1136/jnnp-2016-315018
[11]	He J, Tang L, Benyamin B, et al. C9orf72 hexanucleotide repeat expansions in Chinese sporadic amyotrophic lateral sclerosis[J]. Neurobiol Aging, 2015, 36(9): 2660.e1–2660.e8. doi: 10.1016/j.neurobiolaging.2015.06.002
[12]	Tang J, Yang Y, Gong Z, et al. Plasma uric acid helps predict cognitive impairment in patients with amyotrophic lateral sclerosis[J]. Front Neurol, 2021, 12: 789840. doi: 10.3389/fneur.2021.789840
[13]	Wang X, Sun G, Feng T, et al. Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer's disease progression[J]. Cell Res, 2019, 29(10): 787–803. doi: 10.1038/s41422-019-0216-x
[14]	Chen Y, Xu J, Chen Y. Regulation of neurotransmitters by the gut microbiota and effects on cognition in neurological disorders[J]. Nutrients, 2021, 13(6): 2099. doi: 10.3390/nu13062099
[15]	Matisz CE, Gruber AJ. Neuroinflammatory remodeling of the anterior cingulate cortex as a key driver of mood disorders in gastrointestinal disease and disorders[J]. Neurosci Biobehav Rev, 2022, 133: 104497. doi: 10.1016/j.neubiorev.2021.12.020
[16]	Giau VV, Wu S, Jamerlan A, et al. Gut microbiota and their neuroinflammatory implications in Alzheimer's disease[J]. Nutrients, 2018, 10(11): 1765. doi: 10.3390/nu10111765
[17]	Białecka-Dębek A, Granda D, Szmidt MK, et al. Gut microbiota, probiotic interventions, and cognitive function in the elderly: a review of current knowledge[J]. Nutrients, 2021, 13(8): 2514. doi: 10.3390/nu13082514
[18]	Mccombe PA, Henderson RD, Lee A, et al. Gut microbiota in ALS: possible role in pathogenesis?[J]. Expert Rev Neurother, 2019, 19(9): 785–805. doi: 10.1080/14737175.2019.1623026
[19]	Di Gioia D, Bozzi Cionci N, Baffoni L, et al. A prospective longitudinal study on the microbiota composition in amyotrophic lateral sclerosis[J]. BMC Med, 2020, 18(1): 153. doi: 10.1186/s12916-020-01607-9
[20]	Blacher E, Bashiardes S, Shapiro H, et al. Potential roles of gut microbiome and metabolites in modulating ALS in mice[J]. Nature, 2019, 572(7770): 474–480. doi: 10.1038/s41586-019-1443-5
[21]	Brenner D, Hiergeist A, Adis C, et al. The fecal microbiome of ALS patients[J]. Neurobiol Aging, 2018, 61: 132–137. doi: 10.1016/j.neurobiolaging.2017.09.023
[22]	Niccolai E, Di Pilato V, Nannini G, et al. The Gut Microbiota-Immunity Axis in ALS: A Role in Deciphering Disease Heterogeneity?[J]. Biomedicines, 2021, 9(7).
[23]	Brooks BR, Miller RG, Swash M, et al. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis[J]. Amyotroph Lateral Scler Other Motor Neuron Disord, 2000, 1(5): 293–299. doi: 10.1080/146608200300079536
[24]	Cedarbaum JM, Stambler N, Malta E, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase Ⅲ)[J]. J Neurol Sci, 1999, 169(1–2): 13–21. doi: 10.1016/s0022-510x(99)00210-5
[25]	Zhai C, Zheng J, An B, et al. Intestinal microbiota composition in patients with amyotrophic lateral sclerosis: establishment of bacterial and archaeal communities analyses[J]. Chin Med J, 2019, 132(15): 1815–1822. doi: 10.1097/CM9.0000000000000351
[26]	López-García A, Pineda-Quiroga C, Atxaerandio R, et al. Comparison of mothur and QIIME for the analysis of rumen microbiota composition based on 16S rRNA amplicon sequences[J]. Front Microbiol, 2018, 9: 3010. doi: 10.3389/fmicb.2018.03010
[27]	Hugerth LW, Andersson AF. Analysing microbial community composition through amplicon sequencing: from sampling to hypothesis testing[J]. Front Microbiol, 2017, 8: 1561. doi: 10.3389/fmicb.2017.01561
[28]	Yang J, Wang H, Roberts DJ, et al. Persistence of antibiotic resistance genes from river water to tap water in the Yangtze River Delta[J]. Sci Total Environ, 2020, 742: 140592. doi: 10.1016/j.scitotenv.2020.140592
[29]	Segata N, Izard J, Waldron L, et al. Metagenomic biomarker discovery and explanation[J]. Genome Biol, 2011, 12(6): R60. doi: 10.1186/gb-2011-12-6-r60
[30]	Ridlon JM, Kang DJ, Hylemon PB. Bile salt biotransformations by human intestinal bacteria[J]. J Lipid Res, 2006, 47(2): 241–259. doi: 10.1194/jlr.R500013-JLR200
[31]	Duboc H, Rainteau D, Rajca S, et al. Increase in fecal primary bile acids and dysbiosis in patients with diarrhea-predominant irritable bowel syndrome[J]. Neurogastroenterol Motil, 2012, 24(6): 513–520. doi: 10.1111/j.1365-2982.2012.01893.x
[32]	Staley C, Weingarden AR, Khoruts A, et al. Interaction of gut microbiota with bile acid metabolism and its influence on disease states[J]. Appl Microbiol Biotechnol, 2017, 101(1): 47–64. doi: 10.1007/s00253-016-8006-6
[33]	Rinninella E, Raoul P, Cintoni M, et al. What is the healthy gut microbiota composition? A changing ecosystem across age, environment, diet, and diseases[J]. Microorganisms, 2019, 7(1): 14. doi: 10.3390/microorganisms7010014
[34]	Fang X, Wang X, Yang S, et al. Evaluation of the microbial diversity in amyotrophic lateral sclerosis using high-throughput sequencing[J]. Front Microbiol, 2016, 7: 1479. doi: 10.3389/fmicb.2016.01479
[35]	Rowin J, Xia Y, Jung B, et al. Gut inflammation and dysbiosis in human motor neuron disease[J]. Physiol Rep, 2017, 5(18): e13443. doi: 10.14814/phy2.13443
[36]	Zeng Q, Shen J, Chen K, et al. The alteration of gut microbiome and metabolism in amyotrophic lateral sclerosis patients[J]. Sci Rep, 2020, 10(1): 12998. doi: 10.1038/s41598-020-69845-8
[37]	Ngo ST, Restuadi R, McCrae AF, et al. Progression and survival of patients with motor neuron disease relative to their fecal microbiota[J]. Amyotroph Lateral Scler Frontotemporal Degener, 2020, 21(7–8): 549–562. doi: 10.1080/21678421.2020.1772825
[38]	Nicholson K, Bjornevik K, Abu-Ali G, et al. The human gut microbiota in people with amyotrophic lateral sclerosis[J]. Amyotroph Lateral Scler Frontotemporal Degener, 2021, 22(3–4): 186–194. doi: 10.1080/21678421.2020.1828475
[39]	Sinha SR, Haileselassie Y, Nguyen LP, et al. Dysbiosis-induced secondary bile acid deficiency promotes intestinal inflammation[J]. Cell Host Microbe, 2020, 27(4): 659–670.e5. doi: 10.1016/j.chom.2020.01.021
[40]	Johnson JS, Spakowicz DJ, Hong BY, et al. Evaluation of 16S rRNA gene sequencing for species and strain-level microbiome analysis[J]. Nat Commun, 2019, 10(1): 5029. doi: 10.1038/s41467-019-13036-1
[41]	Wahlström A, Sayin SI, Marschall HU, et al. Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism[J]. Cell Metab, 2016, 24(1): 41–50. doi: 10.1016/j.cmet.2016.05.005
[42]	Gee LMV, Barron-Millar B, Leslie J, et al. Anti-cholestatic therapy with obeticholic acid improves short-term memory in bile duct-ligated mice[J]. Am J Pathol, 2022, 193(1): 11–26. doi: 10.1016/j.ajpath.2022.09.005
[43]	Ding L, Yang L, Wang Z, et al. Bile acid nuclear receptor FXR and digestive system diseases[J]. Acta Pharm Sin B, 2015, 5(2): 135–144. doi: 10.1016/j.apsb.2015.01.004
[44]	Bazzari FH, Abdallah DM, El-Abhar HS. Chenodeoxycholic acid ameliorates AlCl₃-induced Alzheimer's disease neurotoxicity and cognitive deterioration via enhanced insulin signaling in rats[J]. Molecules, 2019, 24(10): 1992. doi: 10.3390/molecules24101992
[45]	Mahmoudiandehkordi S, Arnold M, Nho K, et al. Altered bile acid profile associates with cognitive impairment in Alzheimer's disease-An emerging role for gut microbiome[J]. Alzheimers Dement, 2019, 15(1): 76–92. doi: 10.1016/j.jalz.2018.07.217
[46]	Suhre K, Meisinger C, Döring A, et al. Metabolic footprint of diabetes: a multiplatform metabolomics study in an epidemiological setting[J]. PLoS One, 2010, 5(11): e13953. doi: 10.1371/journal.pone.0013953
[47]	Mertens KL, Kalsbeek A, Soeters MR, et al. Bile acid signaling pathways from the enterohepatic circulation to the central nervous system[J]. Front Neurosci, 2017, 11: 617. doi: 10.3389/fnins.2017.00617

Supplements (1)

Supplements
Other Related Supplements
- PDF format
  JBR-2022-0198-Supplementary Download(876KB)

Cited By

Cited by

Periodical cited type(7)

1.	Pribac M, Motataianu A, Andone S, et al. Bridging the Gap: Harnessing Plant Bioactive Molecules to Target Gut Microbiome Dysfunctions in Amyotrophic Lateral Sclerosis. Curr Issues Mol Biol, 2024, 46(5): 4471-4488. DOI:10.3390/cimb46050271
2.	Feng C, Li N, Gao G, et al. Dynamic Changes of the Gut Microbiota and Its Functional Metagenomic Potential during the Development of Non-Small Cell Lung Cancer. Int J Mol Sci, 2024, 25(7): 3768. DOI:10.3390/ijms25073768
3.	Noor Eddin A, Alfuwais M, Noor Eddin R, et al. Gut-Modulating Agents and Amyotrophic Lateral Sclerosis: Current Evidence and Future Perspectives. Nutrients, 2024, 16(5): 590. DOI:10.3390/nu16050590
4.	Ma YY, Li X, Yu JT, et al. Therapeutics for neurodegenerative diseases by targeting the gut microbiome: from bench to bedside. Transl Neurodegener, 2024, 13(1): 12. DOI:10.1186/s40035-024-00404-1
5.	Loh JS, Mak WQ, Tan LKS, et al. Microbiota-gut-brain axis and its therapeutic applications in neurodegenerative diseases. Signal Transduct Target Ther, 2024, 9(1): 37. DOI:10.1038/s41392-024-01743-1
6.	Guo K, Figueroa-Romero C, Noureldein MH, et al. Gut microbiome correlates with plasma lipids in amyotrophic lateral sclerosis. Brain, 2024, 147(2): 665-679. DOI:10.1093/brain/awad306
7.	Goutman SA, Savelieff MG, Jang DG, et al. The amyotrophic lateral sclerosis exposome: recent advances and future directions. Nat Rev Neurol, 2023, 19(10): 617-634. DOI:10.1038/s41582-023-00867-2

Other cited types(0)

Figures(5) / Tables(3)

Get Citation

PDF

XML

Article Metrics

Article views (915) PDF downloads (123) Cited by(7)

CiteScore

Impact Factor

Gut microbiota links with cognitive impairment in amyotrophic lateral sclerosis: A multi-omics study